Physician profile
Troy R Stiles
NPI 1437122207
$220,521.50
in general payments reported to CMS, 2019-2025
18 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,402 · 2021: $8,257 · 2022: $20K · 2023: $55K · 2024: $25K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Travel and Lodging: $11K · Consulting Fee: $4,530 · Food and Beverage: $3,609 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,152.00 |
| Travel and Lodging | $11,481.03 |
| Consulting Fee | $4,530.00 |
| Food and Beverage | $3,608.51 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $158,844.86 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24,997.67 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $22,508.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12,568.80 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $345.04 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $296.65 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $167.84 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $164.43 | 2019-2025 | Invega |
| Ironshore Pharmaceuticals INC. | $118.02 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $104.20 | 2024-2025 | Fanapt |
| Alkermes, INC. | $103.26 | 2022-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $68.50 | 2019 | |
| Lundbeck LLC | $65.31 | 2019-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $58.26 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $45.29 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.84 | 2023 | Belsomra |
| Allergan, INC. | $22.96 | 2019 | |
| Corium, LLC | $13.54 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Stiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.